Cart (0 Items)
Your cart is currently empty.
View Productssize | 100ug |
---|---|
Brand | ProteoGenix |
Product type | Recombinant Proteins |
Host Species | Mammalian cells |
Applications | Elisa, WB |
Product name | CD122 / IL2RB, C-His, recombinant protein |
---|---|
Origin species | Homo sapiens (Human) |
Expression system | Eukaryotic expression |
Molecular weight | 28.32 kDa |
Protein delivered with Tag? | C-terminal His Tag |
Purity estimated | >90% as determined by SDS-PAGE |
Buffer | PBS, pH7.5 |
Delivery condition | Dry Ice |
Storage condition | 4°C for short term (1 week), -20°C or -80°C for long term (avoid freezing/thawing cycles; addition of 20-40% glycerol improves cryoprotection) |
Brand | ProteoGenix |
Host species | Mammalian cells |
Fragment Type | Met1-Asp239 |
Protein Accession | P14784 |
Reference | PX-P5555 |
Note | For research use only |
CD122, also known as Interleukin-2 Receptor Beta (IL2RB), is a type I transmembrane glycoprotein that belongs to the cytokine receptor superfamily. It is composed of an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain is composed of three immunoglobulin-like domains, while the intracellular domain consists of two tyrosine-based activation motifs.
CD122 is a receptor for Interleukin-2 (IL-2), a cytokine that plays an important role in the regulation of the immune response. The binding of IL-2 to CD122 triggers a series of intracellular signaling pathways, leading to the activation of various downstream molecules such as Janus kinases (JAKs) and signal transducers and activators of transcription (STATs).
CD122 plays an important role in the regulation of the immune response, and its expression has been associated with various immune disorders, such as autoimmune diseases, allergies, and cancer. In addition, CD122 has been studied as a potential target for therapeutic intervention in these diseases.
Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.
Reviews
There are no reviews yet.